Ron Zwanziger has served as our Chairman, Chief Executive Officer and President since our inception on May 11, 2001. Mr. Zwanziger served as Chairman, Chief Executive Officer and President of our predecessor company, Inverness Medical Technology, from its inception in 1992 through November 2001 when that company was acquired by Johnson & Johnson. From 1981 to 1991, he was Chairman and Chief Executive Officer of MediSense, a medical device company.

David Scott
Chief Scientific Officer

David Scott, Ph.D., has served on the Board since July 31, 2001 and is our Chief Scientific Officer. Dr. Scott served as Chairman of Inverness Medical Limited, a subsidiary of our predecessor company, Inverness Medical Technology, from July 1999 through November 2001, when that Company was acquired by Johnson & Johnson, and as a Managing Director of Inverness Medical Limited from July 1995 to July 1999. Dr Scott served as Managing Director of Great Alarm Limited, a consulting company, from October 1993 to April 1995. Between October 1984 and September 1993, he held several positions at MediSense UK, serving most recently as Managing Director where he was responsible for managing product development, as well as the mass manufacture of one of its principle products, ExacTech.

Jerry McAleer
Vice President, Research & Development
Vice President, Cardiology

Jerry McAleer, Ph.D has served as our Vice President, Research and Development since our inception in May 2001. Dr McAleer served as Vice President of Research and Development of our predecessor company, Inverness Medical Technology, from 1999 through November 2001, when that company was acquired by Johnson & Johnson. From 1995 to 1999, Dr. McAleer served as Director of Development of Inverness Medical Limited, Inverness Medical Technology’s primary research and development unit, where he headed the development of Inverness Medical Technology’s electrochemical glucose strips. Prior to joining Inverness Medical Technology, Dr. McAleer held senior research and development positions at MediSense from 1985 to 1993 and then at Ecossensors, Inc., an environmental research company, where he was responsible for the development of electrochemically based assay systems.

 

Hilde Eylenbosch
President, Consumer Diagnostics

Hilde Eylenbosch, M.D., has served as Vice President of the Company and President of our Consumer Diagnostics strategic business unit since April 2005. Prior to this, Dr Eylenbosch was Vice President Consumer Marketing, a position she held since October 2004, and Vice President of International Women’s Health since November 2001. Dr. Eylenbosch served in the same capacity for our predecessor company, Inverness Medical Technology, from August 2001 until that company was acquired by Johnson & Johnson in November 2001. Prior to that she held various positions at Inverness Medical Technology, including Director of US Women’s Health from September 1998 through October 2000. When she joined Inverness Medical Technology in January 1995, Dr Eylenbosch was responsible for marketing that company’s women’s health products in Europe. Before joining Inverness Medical Technology, Dr Eylenbosch was employed by Synthelabo, a French pharmaceutical company, where she held various marketing positions.

 

David Toohey has served as our Vice President, Professional Diagnostics since October 2002 and as President of our Professional Diagnostics strategic business unit since April 2005. Prior to that time he served as our Vice President, European Operations since February 2002, as our Vice President, New Products from November 2001 through February 2002, and as Managing Director of our Unipath Limited subsidiary from December 2001 through October 2002. Mr. Toohey was employed by our predecessor company, Inverness Medical Technology, as its Vice President, New Products from May 2001 through November 2001, when that company was acquired by Johnson & Johnson. Prior to joining Inverness Medical Technology, Mr. Toohey served as Vice President of Operations at Boston Scientific Corporation’s Galway, Ireland facility, Boston Scientific’s largest and most complex manufacturing facility with 2,500 employees. Between 1995 and 2001 he oversaw the growth of that facility from a 100 person start-up, initially serving as General Manager, later as Managing Director and finally as Vice President of Operations. Prior to that time he held various executive positions at Bausch & Lomb, Inc., Digital Equipment Corp. and Mars, Inc.

 

John Yonkin
President, US Point of Care
President, Inverness Medical Nutritionals

John Yonkin serves as President, US Point of Care for our Professional Diagnostics strategic business unit, a role which he assumed in April 2006. He also leads our Nutritionals strategic business unit, as he has done since April 2005. Prior to that Mr. Yonkin served as Vice President of US Sales & Marketing from November 2001. Mr. Yonkin served as Vice President of US Sales of our predecessor company, Inverness Medical Technology, from October 1998 through January 2000 and its General Manager from January 2000 through November 2001, when that company was acquired by Johnson & Johnson. He also served as Manager of Product Development for Inverness Medical Technology from October 1997 until October 1998. From January 1995 to September 1997, Mr. Yonkin was Director of National Accounts for Genzyme Genetics, a subsidiary of Genzyme, Inc., a leader in genetic testing services for hospitals, physicians and managed healthcare companies.

 

Paul T. Hempel
Senior Vice President, Leadership Development & Special Counsel

Paul T. Hempel served as our General Counsel and Secretary from our inception on May 11, 2001 through May 2007. In April 2006, Mr. Hempel became Senior Vice President in charge of leadership development, while retaining his role as Secretary and oversight of legal affairs, and he is now devoted full-time to overseeing Leadership Development at IMI. Mr. Hempel served as General Counsel and Assistant Secretary of our predecessor company, Inverness Medical Technology, from October 2000 through November 2001, when that company was acquired by Johnson & Johnson. Prior to joining Inverness Medical Technology, he was a founding stockholder and Managing Director of Erickson Schaffer Peterson Hempel & Israel PC from 1996 to 2000. Prior to 1996, Mr. Hempel was a partner and managed the business practice at Bowditch & Dewey LLP.

David Teitel
Chief Financial Officer

David Teitel has served as our Chief Financial Officer since December 2006.  Dave joined the Company in December 2003 as Director of Finance Operations and assumed the title Vice President, Finance in December 2004.  Dave has over 20 years of public and private company finance experience, including nine years of audit experience at Arthur Andersen.  From 2001 to 2003, Dave was Chief Financial Officer for an early stage software and service provider to healthcare providers.  Prior to this role, Dave served in a variety of senior financial roles for ThermoElectron, Nextera Enterprises and Dekantel Snowden Pencer.